Response to: "does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation" by Masi and Fleischmann by Boeters, D.M. (Debbie M.) & Helm-van Mil, A.H.M. (Annette) van der
LETTER Open Access
Response to: “Does ACPA-negative RA
consist of subgroups related to sustained
DMARD-free remission and serological
markers at disease presentation” by Masi
and Fleischmann
Debbie M. Boeters1* and Annette H. M. van der Helm–van Mil1,2
With interest, we read the letter of Masi and Fleisch-
mann [1], and we are pleased with the interest in our
study, in which we observed that subgroups can be iden-
tified within ACPA-negative RA when studying serum
markers at disease presentation [2]. Masi and Fleisch-
man had several comments.
First, they noted that the EAC started in 1993 and that
not all RA patients in the cohort were studied, but only
those of the most recent inclusion period (2011–2016).
This is correct. Sustained DMARD-free remission was
infrequent in the past and has become more frequent
over time, with the highest frequency in the most recent
inclusion period [3, 4]. As the outcome should be preva-
lent in order to have sufficient power to detect associa-
tions, we decided to determine serum markers in all
RA patients that were consecutively included in this
most recent inclusion period.
Second, Masi and Fleischmann mentioned that the re-
sults were flawed because age was neglected as potential
confounder. The authors were incorrect. Potential con-
founders were evaluated. Subsequently age, and also
swollen joint count and the presence of rheumatoid fac-
tor, were added as adjustment factors in a multivariable
analysis. After these corrections, the association
remained present and therefore age (or confounders
linked to age) had not biased our results.
Finally, and perhaps most importantly, the authors noted
that it was unexpected that we observed that higher MBDA
scores at diagnosis associated with a lower risk to achieve
sustained DMARD-free remission over time in ACPA-
negative RA, because some previous studies reported that
high MBDA scores related to higher disease activity scores in
cross-sectional analyses and that low MBDA scores were
predictive of achieving DAS-remission, as was recently
shown by Fleischmann [5]. It seems that this misunderstand-
ing is caused by confusing two different study aims. Fleisch-
mann evaluated the MBDA score for the purpose for which
it was developed, which is disease monitoring. We, in con-
trast, had a different and more basic aim. We wanted to in-
crease the comprehension on the mechanisms underlying
the development of sustained DMARD-free remission, and
in line with this, to explore whether patient characteristics at
diagnosis are related to the ability to achieve this long-term
outcome. In previous studies, we observed that several
markers of inflammation measured at diagnosis (swollen
joint counts, C-reactive protein, and MRI-detected joint in-
flammation), poorly relate to this long-term outcome [4, 6].
As C-reactive protein is just one of many markers of inflam-
mation present in the circulation, we now measured other
inflammatory markers. The MBDA score is a tool that com-
bines several markers and was used for practical reasons, but
any other array that combines several proteins would have
been equally interesting to start with. Our data is the first
supporting that ACPA-negative RA consists of several sub-
sets with differences in the long-term outcome that can be
identified at the time of diagnosis. This finding is
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important and incentive to perform subsequent studies.
Ideally, more inflammatory markers should be measured
than the 12 markers that were studied now, in order to
find the combination of markers with the highest discrim-
inative ability. In addition, results need to be validated in
other sets of ACPA-negative RA patients with long-term
follow-up data. Hopefully, further studies on proteomics
(possibly also including expression of other markers) will
be helpful in differentiating ACPA-negative RA in clinic-
ally relevant subsets.
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